Group 1: Praxis Precision Medicines - Praxis Precision Medicines plans to submit an experimental seizure drug, relutrigine, for U.S. approval early next year after discussions with the FDA [2] - Shares of Praxis rose by 2% to close just above $267 following positive updates from a different pipeline program [2] Group 2: Rezolute - Rezolute's drug ersodetug failed a Phase 3 trial for a rare genetic condition causing low blood sugar, not significantly reducing the average number of hypoglycemic events compared to placebo [2] - Following the trial results, Rezolute's share price plummeted by nearly 90%, and Xoma Royalty also experienced a double-digit sell-off [2] Group 3: Geron - Geron announced a layoff of about one-third of its 260 employees as part of a strategic restructuring after stagnating sales of its approved drug Rytelo [2] - The new CEO indicated that cost-cutting measures are aimed at prudent fiscal management, projecting lower operating expenses in 2026 compared to 2025 [2] Group 4: Rhythm Pharmaceuticals - Rhythm Pharmaceuticals will advance its drug setmelanotide into late-stage trials for Prader-Willi syndrome after positive early results in a small Phase 2 study [2] - The study indicated that setmelanotide showed potential in reducing hunger cravings and lowering body mass index values, leading to a 12% increase in shares, which have nearly doubled in value this year [2]